-
Alcon launches Ilevro
NEW YORK — Eye care company Alcon has launched a treatment for pain and inflammation resulting from cataract surgery, the company said Monday.
The company said Ilevro (nepafenac) ophthalmic suspension was a nonsteroidal anti-inflammatory drug and once-daily treatment for cataract surgery patients.
-
GSK submits approval application for albiglutide
LONDON — Drug maker GlaxoSmithKline is seeking Food and Drug Administration approval for a new treatment for Type 2 diabetes, the drug maker said.
GSK announced the submission to the FDA of a regulatory approval application for albiglutide. The drug is not approved in any market yet, and the company plans to also seek approval in the European Union this year.
GSK assumed control of albiglutide with its $3.6 billion acquisition of Human Genome Sciences, announced last July.